title: Systemic induction of cells mediating antibody-dependent cellular cytotoxicity following administration of interleukin 2.
abstract: We have previously demonstrated that incubation of murine cells in vitro in interleukin 2 (IL-2) induced antibody-dependent cellular cytotoxicity (ADCC) and that these cells were derived from the NK/LAK, FcR+ cell population. In the present study we show that in vivo administration of IL-2 to mice induces cells which exhibit ADCC activity in the peritoneal cavity, liver, lungs, and to a lesser degree in the bone marrow, spleen, mesenteric lymph nodes, and thymus. A gradual increase in ADCC activity and the number of Fc-receptor-positive cells was seen 1 to 3 days after starting IL-2 treatment. The cells mediating ADCC are closely related to LAK cells since they expressed Thy1.2 antigens and are derived from asialo GM1-positive, Lyt2/L3T4-negative, radiosensitive cells. These results demonstrate that IL-2 can systemically induce cells with ADCC activity and that this ability may be useful in the establishment of therapeutic models against disseminated cancer when combined with specific antitumor monoclonal antibodies.
authors.affiliation: Surgery Branch, National Institutes of Health, Bethesda, Maryland 20892.
authors.forename: A
authors.initials: A
authors.lastname: Eisenthal
authors.forename: S A
authors.initials: SA
authors.lastname: Rosenberg
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000920:Antibody-Dependent Cell Cytotoxicity / Q000187:drug effects*; D000954:Antigens, Surface / Q000276:immunology; D002478:Cells, Cultured; D003131:Combined Modality Therapy; D005260:Female; D005434:Flow Cytometry; D007376:Interleukin-2 / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000556:secondary; D008212:Lymphocyte Depletion; D008546:Melanoma, Experimental / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D051379:Mice; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D011961:Receptors, Fc / Q000276:immunology; D011994:Recombinant Proteins / Q000627:therapeutic use; D018800:Thy-1 Antigens
chemical_list: D000911:Antibodies, Monoclonal; D000954:Antigens, Surface; D007376:Interleukin-2; D011961:Receptors, Fc; D011994:Recombinant Proteins; D018800:Thy-1 Antigens